To inform future studies of combination immunotherapy in PD-L1(+) patients [39]; Our data provide early insights into the levels of these markers in the TNBC tumor microenvironment and how they relate to chemotherapy response and patient survival [40]. The gene discussed is CD274; the disease is neoplasm.